Hypothesis: Timed supplementation with Akkermansia muciniphila during the early sleep phase enhances glymphatic clearance of gut-derived toxins by synchronizing mucosal barrier repair with the brain’s nocturnal triage. In aging, circulating advanced glycation end products (AGEs) such as N6-carboxymethyllysine leak from a compromised colon and suppress microglial phagocytosis, impairing the sleep-dependent decision‑making process that selects which synaptic architectures persist. Akkermansia muciniphila restores mucus thickness and reduces plasma IL-6, thereby lowering AGE translocation. However, its benefits are transient and depend on functional activity rather than stable colonization. If the bacterium is administered at the onset of non-REM sleep—when glymphatic influx peaks—its barrier-strengthening effect will coincide with the period when cerebrospinal fluid influx clears interstitial solutes, maximizing removal of AGEs before they reach microglia. Conversely, supplementation during wakefulness will miss this window and show little impact on brain clearance. This predicts that aged mice receiving A. muciniphila at zeitgeber time ZT0 (lights off) will exhibit greater fluorescent tracer influx into the brain parenchyma, lower hippocampal IL-6, and improved performance on spatial memory tasks compared with mice receiving the same dose at ZT12 (lights on) or vehicle. The hypothesis is falsifiable: if timed dosing does not increase glymphatic flux or reduce neuroinflammation relative to untimed dosing, the proposed mechanistic link between gut barrier dynamics and sleep-dependent brain autopsy is refuted.

Mechanistically: A. muciniphila-derived propionate activates colonic epithelial HIF-1alpha, boosting MUC2 secretion and tightening the barrier within a few hours. This surge in mucus production reduces luminal AGE absorption, lowering plasma concentrations that would otherwise cross the blood-brain barrier during the sleep-linked increase in cerebrospinal fluid flow. Simultaneously, vagal afferents sense the improved mucosal state and signal the nucleus tractus solitarius, promoting a shift toward slower-wave sleep that amplifies glymphatic pulsations. Reduced AGE burden in the brain lessens microglial NLRP3 inflammasome activation, allowing the nocturnal synaptic triage to favor preservation of synapses with low ubiquitination tags while targeting damaged connections for lysosomal degradation. Thus, the bacterium does not merely clean the gut; it tunes the host's circadian-sleep circuitry to make the brain's autopsy more discerning.

To test this: aged C57BL/6 mice will receive oral A. muciniphila (10^9 CFU) either at ZT0 or ZT12 for two weeks. Glymphatic function will be quantified by intrathecal injection of fluorescently labeled albumin-Alexa647 and longitudinal two-photon imaging of cortical clearance over 6 h post-injection. Sleep architecture will be monitored via EEG/EMG to confirm that ZT0 dosing aligns with increased non-REM delta power. Plasma and CSF AGE levels will be measured by LC-MS/MS, hippocampal IL-6 and TNF-alpha by ELISA, and microglial morphology by Iba1 immunostaining. Behavioral assessment will include the Morris water maze and novel object recognition. Predictions: ZT0-treated mice show >=30% faster tracer clearance, <=25% CSF AGEs, <=20% hippocampal IL-6, and improved escape latency relative to ZT12 and vehicle groups. If no differences emerge, the hypothesis that timed Akkermansia administration gates sleep-dependent brain triage is not supported.

If timed dosing improves clearance but does not alter sleep EEG spectra, the primary effect may be peripheral, acting via circulating mediators that independently boost glymphatic flow independent of central sleep state. Conversely, if sleep architecture shifts without changes in tracer kinetics, the bacterium may influence sleep regulation without directly affecting toxin removal, suggesting a dissociable pathway. Either outcome will refine the model of gut-brain-sleep interplay in aging.